Previous 10 |
home / stock / brtxd / brtxd news
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35 th ...
--Notice of allowance will be the third US patent to issue from this ThermoStem ® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (ȁ...
(NewsDirect) By Julian Richard, Benzinga BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application...
-- Patent provides protection in key international markets for BioRestorative ’ s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes -- ...
(NewsDirect) By Julian Richard, Benzinga Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony discs in the lower back. While its exact cause is ...
(NewsDirect) By Faith Ashmore, Benzinga BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. The company is engaged in developing therapeutic products using cell and tissue protocols, primarily with adu...
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021 MELVILLE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ: BRTX ), a life sciences company focused on ...
News, Short Squeeze, Breakout and More Instantly...
BioRestorative Therapies Inc Company Name:
BRTXD Stock Symbol:
OTCMKTS Market:
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: ...
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem ® licensing opportunities – – Substantive di...
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX ...